Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 18/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | HRH2 | P25021 | 1/20 | 0.73 |
| ▸ | HTR1D | P28221 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | HRH1 | P35367 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | HTR3A | P46098 | 1/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365338 | 0.90 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| Piboserod SCHEMBL30234609 | 0.89 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| Piboserod SCHEMBL467339 | 0.89 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7333331 | 0.89 | HTR4 (0.82) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8423110 | 0.88 | HTR4 (0.79) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| Piboserod SCHEMBL2228911 | 0.88 | HTR4 (0.98) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7374980 | 0.87 | HTR4 (0.78) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL8286732 | 0.86 | HTR4 (1.00) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7328741 | 0.86 | HTR4 (0.75) | HTR4CHRM2ADRA2BHRH2HTR1D | |
| SCHEMBL7398429 | 0.85 | HTR4 (0.88) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176370-A1 | 3,4-Dihdro-N-[[1-(3-hydroxybutyl)-4-piperidinyl]methyl]-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide as 5-HT(4) receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2004-09-09 | — | — | US | disclosed |
| WO-2000017207-A1 | 3,4-DIHYDRO -N-[[1-(3 -HYDROXYBUTYL) -4-PIPERIDINYL] METHYL] -2H-[1,3] OXAZINO[3, 2-A]INDOLE -10-CARBOXAMIDE AS 5-HT(4) RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176370-A1 | 3,4-Dihdro-N-[[1-(3-hydroxybutyl)-4-piperidinyl]methyl]-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide as 5-HT(4) receptor antagonist | HTR4, HTR3A, HTR1D | HTR4 1/4885CHRM2 959/4885ADRA2B 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.